Siponimod (brand name: Mayzent) is a selective sphingosine-1-phosphate (S1P) receptor modulator being investigated for repurposing in Alzheimer's Disease at St. Joseph's Hospital. This trial (NCT06639282) evaluates the safety and efficacy of siponimod in patients with early to moderate AD, leveraging its immunomodulatory properties to target neuroinflammation—a key pathological driver of neurodegeneration.
Siponimod is already approved by the FDA for treating relapsing forms of multiple sclerosis (MS), where it demonstrates robust efficacy in reducing disease activity and disability progression.
| Parameter |
Value |
| NCT Number |
NCT06639282 |
| Status |
Recruiting |
| Phase |
Phase 2 |
| Sponsor |
St. Joseph's Hospital |
| Intervention |
Siponimod (oral) |
| Indication |
Alzheimer's Disease |
Siponimod is a selective S1P receptor modulator that primarily targets:
-
S1P1 receptor: Predominantly expressed on lymphocytes
- Internalizes and degrades S1P1 receptors, preventing lymphocyte egress from lymphoid tissues
- Reduces circulating pro-inflammatory lymphocytes that can infiltrate the CNS
- Decreases CNS immune cell infiltration
-
S1P5 receptor: Expressed on astrocytes and oligodendrocytes
- Modulates glial cell function
- Promotes oligodendrocyte survival and myelination
- May support neuronal protection
flowchart TD
A["Siponimod"] --> B["S1P1 Receptor Modulation"]
A --> C["S1P5 Receptor Modulation"]
B --> D["Lymphocyte Sequestration"]
B --> E["Reduced CNS Inflammation"]
C --> F["Astrocyte Modulation"]
C --> G["Oligodendrocyte Protection"]
D --> H["Lower Peripheral Cytokines"]
E --> I["Reduced Microglial Activation"]
F --> J["Improved Neuroprotection"]
G --> K["Enhanced Myelin Integrity"]
H --> L["Amyloid Clearance Support"]
I --> M["Tau Pathology Modification"]
J --> N["Cognitive Benefit"]
K --> N
L --> N
M --> N
Beyond immune modulation, siponimod may provide direct neuroprotection through:
- Astrocyte modulation: S1P5 receptor signaling influences astrocyte reactivity and function
- Oligodendrocyte support: Promotes survival and function of myelin-producing cells
- Neurotrophic effects: S1P signaling can support neuronal survival pathways
- Blood-brain barrier integrity: May improve BBB function and reduce leakiness
Alzheimer's Disease is characterized by:
- Amyloid-beta (Aβ) plaques: Accumulation of misfolded Aβ peptides
- Neurofibrillary tangles: Hyperphosphorylated tau protein aggregates
- Neuroinflammation: Chronic activation of microglia and astrocytes
- Synaptic dysfunction: Loss of neuronal connections
Neuroinflammation is now recognized as both a consequence and driver of AD pathology. Activated microglia release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that:
- Exacerbate amyloid deposition
- Promote tau pathology
- Accelerate synaptic loss
- Contribute to cognitive decline
The S1P pathway is implicated in AD through multiple mechanisms:
- Microglial activation: S1P receptors regulate microglial phenotype and function
- Astrocyte reactivity: S1P signaling influences astrocyte-mediated neuroinflammation
- Amyloid processing: S1P modulators may influence amyloid precursor protein (APP) processing
- Tau pathology: S1P signaling can affect tau phosphorylation and aggregation
Siponimod's dual action on S1P1 and S1P5 receptors makes it a promising candidate for:
- Reducing peripheral immune cell CNS infiltration
- Modulating resident glial cell reactivity
- Supporting myelin integrity (relevant given oligodendrocyte involvement in AD)
Based on the Phase 2 trial design typical for AD drug repurposing studies:
| Phase |
Duration |
Arms |
| Screening |
4-6 weeks |
N/A |
| Treatment |
52 weeks |
Siponimod vs. Placebo |
| Follow-up |
12 weeks |
Safety monitoring |
- Cognitive: Change from baseline in ADAS-Cog13 or MMSE
- Safety: Adverse events, serious adverse events
- Biomarker: CSF or plasma neuroinflammation markers
- Brain imaging (MRI) for hippocampal volume
- CSF biomarkers (Aβ, tau, p-tau)
- Functional outcomes (ADCS-ADL, CDR)
- Pharmacokinetic assessments
If successful, siponimod could provide:
- Cognitive stabilization: Reduced rate of cognitive decline
- Neuroinflammation reduction: Lower CSF/Plasma inflammatory markers
- Brain volume preservation: Reduced hippocampal atrophy
- Disease modification: Evidence of slowed disease progression
| Approach |
Target |
Status |
| Siponimod |
S1P receptors (neuroinflammation) |
Phase 2 |
| Aducanumab |
Amyloid plaques |
Approved |
| Lecanemab |
Amyloid plaques |
Approved |
| Donanemab |
Amyloid plaques |
Approved |
| Anti-inflammatory approaches |
COX, IL-1 |
Mixed results |
Siponimod represents a novel mechanism targeting neuroinflammation directly rather than amyloid removal.
Siponimod interacts with the broader sphingolipid pathway:
- Sphingosine-1-phosphate (S1P): Bioactive lipid signaling molecule
- Sphingosine kinase (SPHK): Enzyme that produces S1P
- S1P receptors: G-protein coupled receptors (S1P1-S1P5)